netFormulary NHS
Demonstration Formulary
 Search
 Results

Looking for Infliximab found 33 matches

Formulary items 1 match
   
Open monograph to display formulary status BNF Category
  Restricted Drug Infliximab  (Remicade®)
(Infusion) 		Gastro-intestinal system - Cytokine inhibitors - 01.05.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) (10.01.03)
link in drug section NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) (10.01.03)
link in drug section NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) (01.05)
link in drug section NICE TA:329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) (10.01.03)
link in subsection NICE TA130: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (10.01.03)
link in drug section NICE TA130: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (10.01.03)
link in subsection NICE TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab (10.01.03)
link in drug section NICE TA143: Adalimumab, etanercept and infliximab for ankylosing spondylitis (10.01.03)
link in subsection NICE TA143: Adalimumab, etanercept and infliximab for ankylosing spondylitis (10.01.03)
link in subsection NICE TA143: Ankylosing spondylitis - adalimumab, etanercept and infliximab (10.01.03)
link in drug section NICE TA163: Ulcerative colitis (acute manifestations) Infliximab  (01.05.03)
link in drug section NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40) (01.05.03)
link in drug section NICE TA187: Crohns disease - infliximab (review) and adalimumab (review of TA40)  (01.05.03)
link in drug section NICE TA187: Infliximab (review) and adalimumab for the treatment of Crohns disease (10.01.03)
link in drug section NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (08.02.03)
link in drug section NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in subsection NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in subsection NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab  (10.01.03)
link in drug section NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab  (10.01.03)
link in subsection NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (10.01.03)
link in drug section NICE TA329:Infliximab,adalimumab,and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in subsection NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)


 
netFormulary